Sofiva Genomics Co (6615.TWO) Stock Price

Sofiva Genomics Co Price

CLOSED
29.55
​
Market closed

Over the last 11 years Sofiva Genomics Co grew revenue by 2.5% annually, reaching 385.71 M TWD. Earnings per share have declined at 11.5% per year over the last 10 years. For Sofiva Genomics Co, the net margin of -2.4% is down versus 11.2% a few years ago. At today's price the dividend yield works out to roughly 1.02%.

Sofiva Genomics Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sofiva Genomics Co business model & stock analysis

Sofiva Genomics Co., Ltd. generates revenue through its comprehensive suite of genetic testing services, including reproductive medicine testing, prenatal diagnosis for pregnant women, and newborn genetic testing. The company offers pre-implantation genetic diagnosis for embryos, preeclampsia prediction, and neonatal hearing loss and respiratory distress syndrome tests. Personalized genetic testing services encompass human papilloma virus screening, paternity testing, and chronic disease genetic research, while cancer genetic testing targets cancer patients. These services are primarily purchased by healthcare providers, hospitals, and individuals seeking genetic insights for family planning, pregnancy management, and disease prevention. The firm's product portfolio is segmented into reproductive medicine, prenatal care, newborn screening, and cancer diagnostics, each serving distinct medical needs. Reproductive medicine testing focuses on embryo health before implantation, prenatal services address pregnancy complications, and newborn testing identifies early health risks. Cancer genetic testing supports oncology care, providing tailored treatment options. These segments attract a diverse clientele, including fertility clinics, maternity hospitals, and cancer treatment centers. Sofiva Genomics' genetic counseling services complement its testing offerings, enhancing patient understanding and decision-making. The company's services are marketed to medical institutions and direct consumers, with a strong emphasis on preventive healthcare. By addressing critical health phases from conception to cancer diagnosis, Sofiva Genomics captures value across multiple healthcare touchpoints, ensuring recurring demand from both institutional and individual clients.

Frequently asked questions about Sofiva Genomics Co

Converted at the current exchange rate, the Sofiva Genomics Co share trades at 0.82 EUR (29.55 TWD).

The revenue cannot currently be calculated for Sofiva Genomics Co.

The profit cannot currently be calculated for Sofiva Genomics Co.

The P/E ratio cannot be calculated for Sofiva Genomics Co at the moment.

The P/S cannot be calculated for Sofiva Genomics Co currently.

The Eulerpool Quality Score for Sofiva Genomics Co is 2/10.

The ISIN of Sofiva Genomics Co is TW0006615008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Sofiva Genomics Co is 6615.TWO. The ticker symbol is used to trade Sofiva Genomics Co shares on the stock exchange.

Fair ValueTerminal
26.89 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Jan 5, 2017
ISIN
TW0006615008
Cusip
Y806GJ104
Market capitalization
637.98 M TWDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
1.02
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1.49 %
Dividend
Dividend yield
1.02 %
Payout Ratio
-69.21 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
4 years
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
21.00 %
Last updated Nov 22, 2026, 3:47 AM

Sofiva Genomics Co Peer Group

Sofiva Genomics Co FIGI

6615:TT (Taipei Stock Exchange) · BBG00FN8RCG0